Global Pharma Microbiology Testing Kits Market

Microbiology diagnostics devices and equipment are a broad category covering all kinds of items used in microbiology laboratories and used to diagnose infectious diseases by examining pathogens. These devices and equipment included microscopes, slides, test tubes, Petri dishes, growth media (liquid and solid), inoculation loops, pipettes, and tips, incubators, autoclaves, and laminar flow hoods. Some pieces of equipment are permanent, like microscopes and hoods, while others are not, like pipette tips. The main types of microbiology diagnostic devices and equipment are laboratory instruments, and microbiology analyzers. Laboratory instruments are types of instruments such as incubators, gram stainers, bacterial colony counters, petri dish fillers, and automated culture systems that are needed for operations in the laboratories. The micro-biology analyzers involved are microbiology diagnostics instruments and microscopes. The reagents are pathogen-specific kits, and general reagents. The end-users involved are hospitals, diagnostic centres, customer lab service providers, academic institutes, and research institutes. The microbiology diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides microbiology diagnostics devices and equipment market statistics, including microbiology diagnostics devices and equipment industry global market size, regional shares, competitors with a microbiology diagnostics devices and equipment market share, detailed microbiology diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the microbiology diagnostics devices and equipment industry. This microbiology diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global microbiology diagnostic devices and equipment market size will grow from $3.94 billion in 2022 to $4.43 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiology diagnostic devices and equipment market size is expected to grow from $6.35 billion in 2027 at a CAGR of 9.4%. Increasing funding of public and private investments in medical devices is driving the growth of the microbiology diagnostic devices market. Increasing Investments indicate the rising confidence of various private and public players on microbiology diagnostic devices, thereby indicating a progressive increase and stimulating growth. For instance, according to MedTech news, a publisher of new related to medical technology, private equity industry invested $111.8 B (c.$ 151 B) in healthTech industry. Furthermore, globally 96 deals valued at $40.8 billion were completed in medTech vertical. The increasing investments in digital health technologies, artificial intelligence and non-invasive monitoring capability, delivery of gene therapy and regenerative medicines technologies, and customized 3D printing of medical devices are expected to drive the microbiology diagnostic devices market. Unfavourable regulatory scenarios are major restraints in the microbiology diagnosis devices market. In the US, section 510(k) of the Food, Drug, and Cosmetic Act states that every device manufacturer must register with FDA and notify their intent to market a medical device at least 90 days in advance. These pre-market notifications are considered to be lengthy, rigorous, and time-consuming processes for the approval of medical devices. If in case the submission fails due to some uncertainty, the company has to reperform all the tests and resubmit the premarket approval application. For instance, a 'Verticle Autoclave', a microbiology diagnostic device, complies with the strict international directives and standards such as the capacity of 80-120 litre autoclave chamber volume, low sensitivity loads, restrictions on temperature calibration, and a certificate from ISO17025 accreditation lab for temperature, pressure gauges & timer. Next-Generation Sequencing (NGS) technologies are increasing their prevalence in the microbiology diagnostic devices market due to their cost effectiveness, sensitivity to detect low-frequency variants, and comprehensive genomic coverage. Next-Generation Sequencing (NGS) or high throughput sequencing or Massively Parallel Sequencing (MPS) is a method of sequencing genomes with the ability to sequence hundreds to thousands of genes or gene regions and the capability to detect novel resistance genes (ARG) in bacteria. BioMérieux partnered with Illumina to develop bioMérieux EpiSe, an NGS service that will facilitate epidemiological monitoring of bacterial infections and monitor outbreaks in hospitals. Some of the modern next-generation sequencing technologies that help to sequence DNA and RNA include Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent Proton / PGM sequencing, and SOLiD sequencing. On May 26th, 2022, The IVD Regulation seeks to ensure a high level of public health and patient safety taking into account scientific progress, and smooth operation of the single market for these products. These changes by the EU legislation aid in the development of microbiology diagnostic devices, as they focus on providing transparency of information through EUDAMED (the new European database of medical devices), allowing manufacturers to monitor products, stronger clinical evidence, post-market surveillance, and enhance safety improvements. In April 2022, DCN Dx, a US-based manufacturer and developer of point-of-use tests, acquired Biomed Diagnostics for an undisclosed amount. The acquisition would expand DCN Dx’s footprint in the vertical of point-of-use testing and sampling markets for both humans and animals.Biomed Diagnostics is a US-based microbiological testing company. Major players in the microbiology diagnostics devices and equipment market are Becton Dickinnson and Company, Biomerieux, Danaher, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories Inc., Bruker Corporation, Neogen Corporation, Merck KGaA, and Charles River Laboratories International Inc. North America was the largest region in the microbiology diagnostics devices and equipment market in 2022. Asia-Pacific was the second largest region in the global microbiology diagnostic devices and equipment market. The regions covered in the global microbiology diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the microbiology diagnostics devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The microbiology diagnostic devices and equipment consists of sales of instruments such as incubators, autoclave sterilizers, anaerobic culture systems, blood culture systems, gram strainers, microscopes, mass spectrometers, molecular diagnostic instruments, reagents pathogen-specific kits, and general reagents for microbiology diagnostic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global microbiology diagnostic devices and equipment market is segmented - 1) By Type: Laboratory Instruments, Microbiology Analysers 2) By End User: Hospitals, Diagnostic Centres, Customer Lab Service Providers, Academic Institutes, Research Institutes 3) By Laboratory Instruments: Incubators, Gram Stainers, Bacterial Colony Counters, Petri Dish Fillers, Automated Culture Systems 4) By Micro-Biology Analyzers: Microbiology Diagnostics Instruments, Microscopes 5) By Reagents: Pathogen-Specific Kits, General Reagents

Rapid microbiology testing has high sensitivity and less turnover time compared to traditional methods and is used to diagnose infectious diseases or target products by examining pathogens within a short period. The main product types of rapid microbiology testing kits are instruments, reagents, kits, consumables. The various testing types included are growth-based rapid microbiology testing kits, cellular component-based rapid microbiology testing kits, nucleic acid-based rapid microbiology testing kits, viability-based rapid microbiology testing kits, and other rapid microbiology testing kits methods that are used for applications such as clinical disease diagnosis, food, and beverage testing, pharmaceutical and biological drug testing, cosmetics and personal care products testing, environmental testing, research applications, and others. The rapid microbiology testing kits market research report is one of a series of new reports from The Business Research Company that provides rapid microbiology testing kits market statistics, including rapid microbiology testing kits industry global market size, regional shares, competitors with a rapid microbiology testing kits market share, detailed rapid microbiology testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the rapid microbiology testing kits industry. This rapid microbiology testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global rapid microbiology testing kits market grew from $4.36 billion in 2022 to $4.61 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The rapid microbiology testing kits market is expected to grow from $5.78 billion in 2027 at a CAGR of 5.8%. The rising number of infectious diseases is one of the major drivers for the rapid microbiology testing kits market. Rapid diagnostic tests are faster, more reliable, and more widely available than traditional tests. As the number of infectious disease cases increases, the need for tests to confirm these diseases also increases. With the increasing demand for microbiology tests, the need for rapid microbiology tests is increasing as it gives quicker results than normal microbiology tests. For example, according to the Centers for Disease Control and Prevention (CDC) Trusted Source, the number of visits to physician offices with infectious and parasitic diseases as the primary diagnosis was 15.5 million and the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis was 3.7 million per year. The stringent regulations related to rapid microbiology testing kits are a major restraint for the market. This is because scientific validation is a critical part of obtaining regulatory approval for a rapid microbiology testing method. In this regard, various tests such as a test for accuracy, specificity, precision, range, and robustness are mandatory. The processes for evaluating, validating, and implementing rapid microbiology test methods are expensive and time-consuming. This often leads to a delay in the launch of a testing method and adds up to the final cost of the test. For example, the process for approval by the FDA for rapid microbiology testing methods is very time-consuming which alters the normal operating cycle for manufacturers and causes a delay in the commercial launch of the test devices in the market. Technological advancements are an emerging trend in the rapid microbiology testing kits market. This is mainly because these technological advancements improve the reliability and efficiency of tests and testing methods. Automation in rapid microbial detection enables higher throughputs and greater accuracy in results. Similarly, robotic cassette handling, incubation, and imaging reduce the risks of miscounts, mid-test contamination, and incorrect data entry, which leads to fewer false positives and out-of-specification investigations. Fewer investigations then ultimately improve uptime and reduce delay and recall of tests. For example, Abbott Laboratories announced the next generation Alinity HQ Hematology Analyzer that is aimed to minimize errors and reduce manual steps in testing. The FDA regulates rapid microbiology testing through its process analytical technology (PAT) regulatory framework initiative. PAT is a system that evaluates the designing, controlling, and timely measuring of critical quality of raw and processed materials. It seems that manufacturers have built-in quality into products rather than testing quality in products. This ensures final product quality and improves manufacturing efficiencies. Hence, regulations such as these would keep a check on the companies in the rapid microbiology testing market. Major players in the rapid microbiology testing kits market are Abbott Laboratories, Becton, Dickinson and Company, Bruker Corporation, Charles River Laboratories International Inc., Danaher Corporation, Don Whitley Scientific Limited, Merck KGaA, Neogen Corporation, Quidel Corporation, and Rapid Micro Biosystems Inc. North America was the largest region in the rapid microbiology testing kits market in 2022. Western Europe was the second largest region in the global rapid microbiology testing kits market report. The regions covered in global rapid microbiology testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the rapid microbiology testing kits market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The rapid microbiology testing market includes revenues earned by entities by qualitative, quantitative, and identification methods. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global rapid microbiology testing kits market is segmented - 1) By Product Type: Instruments, Reagents And Kits, Consumables 2) By Application: Clinical Disease Diagnosis, Food And Beverage Testing, Pharmaceutical And Biological Drug Testing, Cosmetics And Personal Care Products Testing, Environmental Testing, Research Applications, Other Applications 3) By Testing Type: Growth-Based Rapid Microbiology Testing Kits, Cellular Component-Based Rapid Microbiology Testing Kits, Nucleic Acid-Based Rapid Microbiology Testing Kits, Viability-Based Rapid Microbiology Testing Kits, Other Rapid Microbiology Testing Kits Methods

Drug screening is an approach used for drug testing, identified and optimized for clinical trials used in the analysis of blood, urine, hair, or saliva to detect the presence of chemicals and pollutants and other illicit substance left in the body as a result of drug usage. The main types of drug screening products include rapid testing devices, consumables, and others. Rapid testing devices refer to easy-to-use drug screening devices that provide results quicker than the standard traditional laboratory test. The different samples used in drug screening includes oral fluid sample, hair sample, urine sample, breath sample, and others. They are used in drug testing laboratories, workplaces, criminal justice and law enforcement, hospitals, drug treatment centers, individual users, pain management centers, schools & colleges. The drug screening market research report is one of a series of new reports from The Business Research Company that provides drug screening market statistics, including drug screening industry global market size, regional shares, competitors with a drug screening market share, detailed drug screening market segments, market trends and opportunities, and any further data you may need to thrive in the drug screening industry. This drug screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drug screening market size grew from $6.62 billion in 2022 to $7.51 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The drug screening market size is expected to grow to $12.29 billion in 2027 at a CAGR of 13.1%. Growing drug and alcohol consumption is driving the growth of the drug screening market. Drug addiction is a disease that affects a person's brain and behavior, resulting in the inability to control the use of a legal or illegal drug or medication. Substances such as alcohol, marijuana, and nicotine also are considered drugs. As the drug and alcohol addiction increases, the chances of disease are higher which triggers the need for drug screening. For instance, in June 2019 & 2020, according to a report published by the United Nations Office on Drugs and Crime (UNODC), 35 million people globally suffer from drug use disorders and require treatment services. The severity and complexity of the world drug situation are increasing, revealing that the number of people who use drugs is now 30% higher than in 2009. The pandemic effects also ramp up drug risks, as cannabis intake by youth had increased by as much as four times in parts of the world. Therefore, growing drug and alcohol consumption is driving the growth of the drug screening market. The development of innovative products is a key trend gaining popularity in the drug screening market. Major companies operating in the drug screening market are focusing on providing innovative products to meet fast-growing industry demand and strengthen their market position. Additionally, due to COVID, there was a sudden change in the drug screening approach, which changed the screening methodologies and pushed the innovation and new product development by companies. Companies are striving to develop new products such as a new drug test that is more effective and can be widely used by laboratories. For instance,in November 2020, Axion BioSystems, a US-based life science company, launched the Maestro ZHT high-throughput screening technology, utilizing their knowledge of live-cell equipment to give drug discovery and development a unique perspective. The Maestro ZHT tackles the challenges of finding and evaluating new candidates, capturing complex biology with a straightforward assay, and minimizing cost, time, and the waste of priceless antibodies and cells with a simple, automated, real-time, live-cell assay. In January 2020, StemBioSys, Inc., a Texas-based company involved in the development, manufacturing and distribution of life science tools acquired a majority stake in CarTox, Inc. for an undisclosed amount. This acquisition is expected to boost the company’s product portfolio in the drug screening and drug toxicology sector and contribute to its strategy to expand its business presence across the globe. CarTox, Inc. is a Michigan-based developer and manufacturer of drug screening and drug toxicology solutions. Major players in the drug screening market are LabCorp, Quest Diagnostics, Alere, OraSure, Alfa Scientific Designs, Thermo Fisher Scientific, Drägerwerk, LifeLoc, Omega Laboratories, Premier Biotech, Intoximeters, Sciteck Inc., Synens SAS, AccuSource Inc., and Creative Diagnostics. North America was the largest region in the drug screening market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug screening market consists of sales of testing kits, reagents, and other supplies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global drug screening market is segmented - 1) By Products: Rapid Testing Devices, Consumables, Other Products 2) By Sample Type: Oral Fluid Sample, Hair Sample, Urine Sample, Breath Sample, Other Sample Types 3) By End User: Drug Testing Laboratories, Workplaces, Criminal Justice and Law Enforcement Agencies, Hospitals, Drug Treatment Centers, Individual Users, Pain Management Centers, Schools and Colleges

Antimicrobial susceptibility testing (AST) is a laboratory procedure done by clinical laboratory professionals to identify which antimicrobial specimen is specifically effective for individual patients. The antimicrobial susceptibility testing market consists of sales of antimicrobial susceptibility testing by entities (organizations, sole traders and partnerships) that are engaged in laboratory services that provide antimicrobial susceptibility testing. The main types of antimicrobial susceptibility testing (AST) procedures are antibacterial testing, antifungal testing, antiparasitic testing and others. Antifungal susceptibility testing refers to the ability of a specific organism to grow in vitro in the presence of a particular drug. AST products that are used in the testing are manual antimicrobial susceptibility testing products, automated laboratory instruments, and other consumables. These are used for diagnostics, drug discovery and development, and epidemiology. Antimicrobial susceptibility testing is used by hospitals and diagnostic centres, pharmaceutical and biotechnology companies, research and academic institutes, and clinical research organizations (CROs). The antimicrobial susceptibility testing market research report is one of a series of new reports from The Business Research Company that provides antimicrobial susceptibility testing market statistics, including antimicrobial susceptibility testing industry global market size, regional shares, competitors with an antimicrobial susceptibility testing market share, detailed antimicrobial susceptibility testing market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial susceptibility testing industry. This antimicrobial susceptibility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antimicrobial susceptibility testing market size grew from $3.67 billion in 2022 to $3.91 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antimicrobial susceptibility testing market size is expected to grow to $4.94 billion in 2027 at a CAGR of 6.0%. The rising incidence of infectious diseases globally contributed to the growth of the antimicrobial susceptibility testing market. Infectious diseases are caused by organisms like bacteria, viruses, fungi and parasites. Diseases caused by bacteria are bacterial pneumonia, tuberculosis, the virus smallpox, AIDS and others. According to World Health Organization (WHO), in 2021, , an estimated 10.6 million people are infected with tuberculosis globally, 1.6 million died , and 1.5 million people acquired HIV in 2021 while 650,000 people lost lives due to it. This increase in the incidence of infected people boosted the use of susceptibility testing of the organisms to develop the most effective drugs and this, in turn, drove the market for antimicrobial susceptibility testing. Rapid antimicrobial susceptibility testing is increasingly being used to avoid misuse of antibiotics and to provide effective treatment and this is emerging as a key trend in the antimicrobial susceptibility testing market. There are many ways to perform antimicrobial susceptibility testing in minutes or a few hours. FISH (Fluorescence in situ hybridization) is mostly used in rapid antimicrobial susceptibility testing. The PNA-FISH applies peptide nucleic acid probes that allow rapid and specific binding, this process is applied in QuickFish technology (OpGen) which performs identification of microbial by targeting 16s RNA. For instance, the antimicrobial susceptibility testing system by Genefluidics Inc measures bacterial growth by quantifying 16s rRNA molecules using an electrochemical biosensor. Major players in the antimicrobial susceptibility testing market are BioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Accelerate Diagnostics, Hi-Media Laboratories, Creative Diagnostics, Merck KGaA, Roche Diagnostics Limited, BD, Alifax Holding S.p.A., Synbiosis, Zhuhai DL Biotech Co, Mast Group, ELITechGroup, Genefluidics, Mast Group, CONDALAB, and QuantaMatrix. North America was the largest region in the antimicrobial susceptibility testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the antimicrobial susceptibility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antimicrobial susceptibility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimicrobial susceptibility testing (AST) market includes revenues earned by dilution susceptibility tests and disc diffusion susceptibility tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antimicrobial susceptibility testing market is segmented - 1) By Type: Antibacterial Testing, Antifungal Testing, Antiparasitic Testing, Other Types 2) By Products: Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, Consumables 3) By Application: Diagnostics, Drug Discovery and Development, Epidemiology, Other Applications 4) By End User: Hospitals And Diagnostic Centers, Pharmaceutical And Biotechnology Companies, Research And Academic Institutes, Clinical Research Organizations (CROs)

Synthetic biology is a field of biological science that involve engineering principles to redesign organisms to give them new abilities. It is possible to think of synthetic biology as the culmination or the prescriptive, deliberate stage of biology. The main product types of synthetic biology are oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), and chassis organisms. Oligonucleotides are small single-stranded DNA segments that, when internalized by the cell, can specifically suppress the expression of a single protein. The various technologies include nucleotide synthesis and sequencing, bioinformatics, microfluidics, and genetic engineering that are applied in pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, and others. The synthetic biology market research report is one of a series of new reports from The Business Research Company that provides synthetic biology market statistics, including synthetic biology industry global market size, regional shares, competitors with a synthetic biology market share, detailed synthetic biology market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic biology industry. This synthetic biology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global synthetic biology market will grow from $13.11 billion in 2022 to $17.07 billion in 2023 at a compound annual growth rate (CAGR) of 30.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global synthetic biology market is expected to grow to $39.12 billion in 2027 at a CAGR of 23.0%. DNA sequencing is important in the development of the synthetic biology in many ways. DNA sequencing finds its use in many synthetic biology applications, therefore the availability of the DNA sequencing technique at low cost drives the production of products based on the applications of synthetic biology. DNA sequencing allows the researchers to determine the DNA sequences in genes and helps a researcher to create a repository of entire genomes. These repositories form the basis for the implementation of synthetic biology applications such as protein expression, directed evolution, and metabolic engineering. According to the Human Genome Research Institute, in 2021,, costs per genome sequenced have decreased from $3 billion to approximately $300 million over the past 17 years and are projected to be gradually lowered by 10 times over the next five years. The bio-safety risks involved in synthetic biology restrains the synthetic biology market. Synthetic biology involves researches on micro-organism to perform the desired function or produce a biological desired substance. Such processes possess health risks such as illness, and allergies in humans as well as environmental risks such as toxicity and risk of new micro-organisms affecting living creatures in the ecosystem. Such potential risks pose as a deterrent to possible innovative research that could be done in certain fields such as combating epidemics such as Ebola and life-threatening diseases such as cancer. The new technological advances in the field of DNA sequencing has enabled the researchers to use DNA to store non-genetic information. With the rise in the demand to store quantum of data, DNA data storage offers a solution where one DNA strand can store about 455 Exabyte of data (455 billion gigabytes). Thus, the concept has received huge investments from the entities in the market. The binary data (data coded in 0O and 1) is converted into DNA strings of four potential base units of unique sequences of A, G, C, T (DNA is made up of four base components: Adenine, Guanine, Cytosine, and Thymine (known as AGCT)). The information coded in DNA lasts for thousands of years when compared to the data in traditional hard drives which gets corrupted or damaged within 30 years. For instance, according to a journal published by Nature Publishing Group, Microsoft and University of Washington researchers stored 35 distinct digital files in DNA—more than 200 megabytes of data and plans to increase future investment to improve the technology. In March 2020, Zymergen, a California-based material innovation company rethinking biology and reimagining the world acquired enEvolv, Inc. for an undisclosed amount. This acquisition speeds Zymergen delivery of high performance and sustainable products to customers and further cements Zymergen leadership position in the bio-manufacturing space. enEvolv, Inc., a next-generation synthetic biology company that has developed an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. Major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris, Twist Bioscience Corporation, Novozymes, New England Biolabs, Synthetic Genomics, Ginkgo Bioworks, Intrexon, E. I. Du Pont De Nemours and Company, Koninklijke DSM N.V., Codexis, Merck KGaA, Danaher Corporation, EnBiotix, Evonetix, Prokarium, Eurofins Scientific, Origene technologies, Pareto Biotechnologies, Blue heron, Syntrox, ATUM, and DNA2.0. North America was the largest region in the synthetic biology market in 2022. Western Europe was the second largest region in the global synthetic biology market. The regions covered in the global synthetic biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the synthetic biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The synthetic biology market includes revenue earned by synthetic compound, technology and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global synthetic biology market is segmented - 1) By Technology: Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering 2) By Application: Pharmaceuticals And Diagnostics, Chemicals, Biofuels, Bioplastics, Other Applications 3) By Product Type: Oligonucleotides, Enzymes, Cloning and Assembly Kits, Xeno-nucleic Acids (XNA), Chassis Organism

Computational biology refers to the field of science that teaches students how to use computer science, statistics, and mathematics to solve biological problems. A wide range of biological disciplines, including genomics/genetics, biophysics, cell biology, biochemistry, and evolution, are included in computational biology. The main types of computational biology are in-house and contract. The in-house market consists of sales of computational biological solutions that are performed within a company. The firm uses its own employees and time to perform a business activity, such as financing or brokering. The various tools applied are databases, infrastructure (hardware), and analysis software and services that are used in applications such as cellular and biological simulation, drug discovery and disease modelling, and clinical trials. The industries that have adopted computational biology are research, the pharmaceutical industry, and commercial applications. The computational biology market research report is one of a series of new reports from The Business Research Company that provides computational biology market statistics, including computational biology industry global market size, regional shares, competitors with a computational biology market share, detailed computational biology market segments, market trends and opportunities, and any further data you may need to thrive in the computational biology industry. This computational biology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global computational biology market size grew from $5.97 billion in 2022 to $7.15 billion in 2023 at a compound annual growth rate (CAGR) of 19.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The computational biology market size is expected to grow to $15.07 billion in 2027 at a CAGR of 20.5%. Government funding has been the major driver in the computational biology market. Governments across the globe are funding infrastructure and academic courses to improve the capabilities of computational biologics in R&D, educational institutions, and other sectors. The rapid growth in government funding is expected to boost the demand for computational biological solutions, as they are widely used in R&D, clinical research, and other development activities. According to the study published in National Cancer Institute, the annual funding for cancer research and biological research increased from $5.9 billion in 2018 to $6.4 billion in 2020. Therefore, government funding is driving the growth of the computational biology market. Computational bio-modelling is a key trend gaining popularity in the computational biologics market. Computational bio-modelling involves mathematical representation of the biological process to study complex behavior. The companies operating in computational biologics are offering innovative services in computational bio-modelling to accelerate development activities. For instance, in 2020, Zymvol, a Spain-based provider of enzyme discovery and design services, launched new services in a combination of molecular modelling and bioinformatics to accelerate enzyme discovery and design services. In March 2022, ZS Associates, a US-based provider of professional services acquired Intomics for an undisclosed amount. Through this acquisition, ZS Associates is focused on diversifying their business activities and offering its clients innovative solutions. Intomics is a Denmark-based provider of bioinformatics solutions and system biology. Major players in the computational biology market are Accelrys, Certara, Chemical Computing Group Inc., Compugen Ltd., Entelos, Inc., Genedata AG, Rhenovia Pharma SAS, Simulation Plus Inc., Schrodinger, Leadscope, Agilent Technologies, Inc., Biomax Informatics AG, DNAnexus, Inc., SOPHiA GENETICS, and Waters Corporation. North America was the largest region in the computational biology market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the computational biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the computational biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The computational biology market includes revenues earned by entities by providing biological notions rigor and verifiability, as well as by offering a framework that connects diverse insights. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global computational biology market is segmented - 1) By Services: In-house, Contract 2) By Tools: Databases, Infrastructure (Hardware), Analysis Software and Services 3) Application: Cellular and Biological Simulation, Drug Discovery and Disease Modelling, Clinical Trials 4) End Users: Research, Pharmaceutical Industry, Commercial Applications

Central lab is a lab that provides bundled services where all of the samples from the trial's clinical locations are submitted. This ensures that the results and analysis are consistent. The main types of services in the central lab are genetic services, biomarker services, microbiology services, anatomic pathology and histology, specimen management and storage, special chemistry services, and others. Genetic services are services that identify and counsel those who are at risk for genetic abnormalities. The different test types include human and tumor genetics, clinical chemistry, medical microbiology and cytology, and other esoteric tests that are employed in several end-users such as pharmaceutical companies, academic and research institutes, and biotechnology companies. The central lab market research report is one of a series of new reports from The Business Research Company that provides central lab market statistics, including central lab industry global market size, regional shares, competitors with a central lab market share, detailed central lab market segments, market trends and opportunities, and any further data you may need to thrive in the central lab industry. This central lab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global central lab market size grew from $2.52 billion in 2022 to $2.74 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The central lab market size is expected to grow to $3.64 billion in 2027 at a CAGR of 7.3%. The rise in the number of clinical trials is expected to drive the central lab market going forward. A clinical trial is a type of research study that is aimed at evaluating a new treatment, a new drug, or a medical device’s safety and effectiveness. Pharmaceutical and biotechnology companies outsource central labs for testing, development, and production of new products. For instance, according to ClinicalTrials.gov, a registry of clinical trials by the National Library of Medicine and a US-based medical library operated by the US federal government, as of July 2022, 422,646 clinical trials were listed as compared to 399,523 in 2021. Therefore, the rise in the number of clinical trials will promote the central lab market. Technological advancements are a key trend gaining popularity in the central lab market. Major companies operating in the central lab sector are focused on developing new technological solutions to strengthen their position in the market. For example, in December 2021, Instron, a US-based manufacturer of a wide range of cutting-edge materials testing equipment, introduced BluehillCentral Lab management software that allows lab administrators to remotely use Bluehill Central Lab regardless of the quantity or location of test systems. The new Bluehill Central software streamlines the lab administration procedure by managing Instron systems and data at the enterprise level using a single database. With this platform, lab administrators can remotely manage a variety of operations across all the frames on their network, including all Bluehill Universal users and permissions, test method templates, results, file revision approvals, and audit trail information. In December 2021, Thermo Fisher Scientific, a US-based supplier of scientific instrumentation, reagents and consumables, and software services, acquired PPD Inc. for $17.4 billion. The acquisition is expected to strengthen Thermo Fisher's capabilities and help it become an industry leader in clinical research services. PPD, Inc. (Pharmaceutical Product Development), is a US-based contract research organization providing comprehensive, integrated drug development, laboratory, and lifecycle management services. Major players in the central lab market are Acm Global Laboratories Private Limited, Cerba Research, Sonic Healthcare Limited, Celerion Inc., Cirion Biopharma Research Inc., Clinical Reference Laboratory Inc., Eurofins Central Laboratory LLC, Frontage Laboratories Inc., Icon Central Labs, Interlab Central Lab Services, InVitro International, Labcorp Drug Development India Private Limited, LabConnect LLC, Medpace Clinical Research India Private Limited, MLM Medical Labs GmbH, Synevo Central Lab, and Q2 Solutions Pty Ltd. North America was the largest region in the central lab market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central lab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the central lab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The central lab market includes revenues earned by entities by providing services such as specimen management, kit and logistics, and clinical trial data analytics services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global central lab market is segmented - 1) By Service Type: Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology or Histology, Specimen Management And Storage, Special Chemistry Services, Other Service Types 2) By Test Type: Human And Tumor Genetics, Clinical Chemistry, Medical Microbiology And Cytology, Other Esoteric Tests 3) By End-User: Pharmaceutical Companies, Academic And Research Institutes, Biotechnology Companies

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices